TERT-TP53突变:一种用于肝细胞癌复发和预后的新生物标志物对

Jin Li1,2, Ling Bai1,2, Zhaodan Xin1,2

  • 1Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.

Scientific reports
|January 29, 2025
PubMed
概括

肝细胞癌 (HCC) 复发风险是由Telomerase逆转录酶 (TERT) 促进体和细胞瘤抗原p53.3的突变预测的. 这些突变的同时发生表明肝癌患者的预后不佳.